All In MedTech

Device Trial Radar · NCT07950436

Esprit BTK Japan Post-Marketing Surveillance

Esprit BTK Everolimus Eluting Resorbable Scaffold System - Japan Post-Marketing Surveillance Protocol Using the J-EVT Database

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

155

Actual

Start

Oct 3, 2025

Primary completion

Aug 25, 2027

Study completion Sep 19, 2031

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Nov 20, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Esprit BTK Japan Post-Marketing Surveillance (PMS) is a database-based PMS. The purpose of this PMS is to confirm the safety and effectiveness of the Esprit BTK Everolimus Eluting Resorbable Scaffold System for the treatment of below-the-knee artery disease in the real-world clinical setting in Japan. The Surveillance will register all patients in whom treatment with Esprit BTK was attempted.

Conditions

  • Chronic Limb-Threatening Ischemia

Interventions

  • Esprit BTK Everolimus Eluting Resorbable Scaffold SystemDevice

    The Esprit BTK implant procedure is as follows: 1. If any inflow artery (non-target vessel) needs to be treated, it will be first treated before implanting Esprit BTK 2. If more than one stenosed and/or occlusive arteries were observed, the lesion(s) in the artery which is suspected to be "culprit" will be treated with Esprit BTK, if possible, as the target lesion(s). 3. If any IP lesion needs to be treated without using Esprit BTK, it will be first treated as a non-target lesion before implanting Esprit BTK. 4. Target lesions will be pre-dilated. 5. Esprit BTK will be implanted only when the target lesion is successfully predilated as determined by the operator. 6. Esprit BTK will be implanted according to the IFU and the proper device use policy established by CVIT and associated professional societies. The entire pre-dilated segment should be covered with scaffold(s). 7. After successful Esprit BTK implantation, the target lesion will be post-dilated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from Major Adverse Limb Event (MALE) + Peri-Operative Death (POD)Time frame: 6 Months

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Osaka Police Hospital

    Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.